According to the World Health Organization, sterility is defined as the “failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse”. In order to overcome such complications, many couples try assisted reproductive technologies (ART), whereas the othres use antioxidants avoiding ART, hoping to improve their fertility.
We conducted a multicenter evaluation of the effectiveness and safety of the Miraxant dietary supplement for treating males with idiopathic sterility. The aim of the study was to analyze the spermogram parameters (sperm cells concentration, motility, morphology and viability) and hormonal levels (testosterone, sex hormone-binding globulin, follicle stimulating hormone, luteinizing hormone and inhibin B). The study comprised 86 men undergoing treatment of sterility. The mean age of patients was 31.6 ± 5.8 years (from 19 to 45 years). The mean duration of sterile marriage was 14.2 ± 6.9 months.
After the treatment, the following effects were reported: a significant improvement of sperm cell motility by 22.5% (by the third month of treatment), and an increase of their viability by 11.9%. This prospective non-comparative study on Miraxant has demonstrated its clinical effectiveness in 56.7% of men and safety in treating idiopathic steriliry.
According to the results of the study, it is advisable to use the Miraxant dietary supplement as a part of a complex therapy of men with idiopathic pathospermia.
Authors declare lack of the possible conflicts of interests